MedPath

DUREZOL

These highlights do not include all the information needed to use DUREZOL safely and effectively. See full prescribing information for DUREZOL. DUREZOL (difluprednate ophthalmic emulsion)Initial U.S. Approval: 2008

Approved
Approval ID

830dd64e-8b1a-4bc4-86bd-e0a0915b59e7

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 27, 2023

Manufacturers
FDA

Novartis Pharmaceuticals Corporation

DUNS: 002147023

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

difluprednate

PRODUCT DETAILS

NDC Product Code0078-0862
Application NumberNDA022212
Marketing CategoryC73594
Route of AdministrationOPHTHALMIC
Effective DateNovember 15, 2020
Generic Namedifluprednate

INGREDIENTS (10)

DIFLUPREDNATEActive
Quantity: 0.5 mg in 1 mL
Code: S8A06QG2QE
Classification: ACTIB
BORIC ACIDInactive
Code: R57ZHV85D4
Classification: IACT
CASTOR OILInactive
Code: D5340Y2I9G
Classification: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8H
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM ACETATEInactive
Code: 4550K0SC9B
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
EDETATE DISODIUMInactive
Code: 7FLD91C86K
Classification: IACT
SORBIC ACIDInactive
Code: X045WJ989B
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DUREZOL - FDA Drug Approval Details